Reduced nitric oxide production by L-arginine deficiency in lysinuric protein intolerance exacerbates intravascular coagulation.
Lysinuric protein intolerance (LPI) results in low serum L-arginine, hyperammonemia, mental retardation, thrombocytopenia, and an increased frequency of bowel movements. Our objective was to evaluate the effects of low serum L-arginine, the essential substrate for reactions catalyzed by nitric oxide synthetase (NOS), on the serum nitric oxide (NO) level and coagulation activity in a patient with LPI. A 37-year-old Japanese man who presented with abdominal pain and subnormal fasting levels of serum L-arginine and L-lysine was found to have LPI. The result of oral administration of diamino acids was an increased in urine and a decrease in serum, thus confirming the diagnosis. A decrease in the platelet count and an increase in the plasma levels of thrombin-antithrombin III complex (TAT) and fibrin degradation products (FDPs) indicated the presence of subclinical intravascular coagulation. Serum levels of NO derivatives and L-arginine were determined after intravenous administration of L-arginine. The effects of intravenous L-arginine or transdermal nitroglycerin on the plasma level of TAT were also investigated. Serum levels of NO derivatives were significantly reduced in the LPI patient versus the healthy control group (n = 5). Intravenous administration of L-arginine increased the serum level of NO derivatives and the platelet count and reduced plasma TAT and FDP levels. The plasma level of TAT was also reduced by transdermal nitroglycerin. A decrease in the serum level of L-arginine in patients with LPI appears to result in a decrease in NO production. The improvement in plasma TAT levels produced by administration of intravenous L-arginine or transdermal nitroglycerin suggests that intravascular coagulation is exacerbated by the decrease of NO production in patients with LPI.
Kayanoki
Y
Y
Second Department of Internal Medicine, Osaka University Medical School, Suita, Japan.
Kawata
S
S
Yamasaki
E
E
Kiso
S
S
Inoue
S
S
Tamura
S
S
Taniguchi
N
N
Matsuzawa
Y
Y
D000328:Adult; D000592:Amino Acid Metabolism, Inborn Errors / Q000097:blood* / Q000473:pathology; D000990:Antithrombin III; D001120:Arginine / Q000097:blood* / Q000494:pharmacology / Q000652:urine; D001778:Blood Coagulation Disorders / Q000097:blood* / Q000473:pathology; D002956:Citrulline / Q000097:blood; D006152:Cyclic GMP / Q000097:blood; D006801:Humans; D008239:Lysine / Q000097:blood / Q000652:urine*; D008297:Male; D009569:Nitric Oxide / Q000097:blood*; D005996:Nitroglycerin / Q000494:pharmacology; D009952:Ornithine / Q000097:blood / Q000652:urine; D010447:Peptide Hydrolases; D010974:Platelet Aggregation / Q000187:drug effects; D013927:Thrombosis / Q000473:pathology
C046193:antithrombin III-protease complex; D002956:Citrulline; D009569:Nitric Oxide; D000990:Antithrombin III; D001120:Arginine; D009952:Ornithine; D010447:Peptide Hydrolases; D005996:Nitroglycerin; D006152:Cyclic GMP; D008239:Lysine